Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genscript BiotechGNNSF +5.68%73 3-1 Month Momentum % is 25.00% as of Sep. 02, 2026. GuruFocus rates GNNSF with a GF Score™ of 73/100 and a GF Value™ of $2.36 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,383 Biotechnology companies, Genscript Biotech ranks better than 96.67% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-02), Genscript Biotech's 3-1 Month Momentum % is 25.00%.
The industry rank for Genscript Biotech's 3-1 Month Momentum % or its related term are showing as below:
GNNSF's 3-1 Month Momentum % is ranked better than 96.67% of 1383
companies
in the Biotechnology industry
Industry Median: -9.29
vs GNNSF: 25.00
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Genscript Biotech 3-1 Month Momentum % Related Terms
GNNSF vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Genscript Biotech's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a 3-1 Month Momentum % of 25.00% as of Sep. 02, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Genscript Biotech and its competitors. According to the industry distribution chart, Genscript Biotech ranks #46 out of 1383 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Genscript Biotech's 3-1 Month Momentum % too high?
Genscript Biotech's current 3-1 Month Momentum % is 25.00%. Based on the distribution chart, Genscript Biotech ranks #46 out of 1383 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genscript Biotech has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #46 out of 1383 companies for 3-1 Month Momentum %. This places Genscript Biotech in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Genscript Biotech and its competitors. Genscript Biotech's current 3-1 Month Momentum % is 25.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.36, compared to a current price of $4.65 — trading 97% above its estimated fair value. The current 3-1 Month Momentum % is 25.00%. Genscript Biotech's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current 3-1 Month Momentum % is 25.00% as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be overvalued.
The current stock price of $4.65 is trading 97% above its estimated GF Value™ of $2.36.
GuruFocus considers Genscript Biotech to be Significantly Overvalued.
Key valuation signals for GNNSF:
3-1 Month Momentum %: 25.00%
GF Value™: $2.36 vs. price of $4.65 (97% above fair value)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
73GF Score
Get the complete analysis for GNNSF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
